Journal of addiction medicine
Audio Summaries

Implementation of Dyadic Care to Support Clinical, Administrative, and Service Wraparound Needs for the Opioid-Exposed Mother and Infant

Jun 24, 2026

The authors aimed to evaluate the implementation of dyadic care models for opioid-exposed mothers and infants, addressing the lack of practical guidance in this area. Through a comparative analysis of five outpatient programs, they identified commonalities and differences in clinical, administrative, and service wraparound practices, revealing that while dyadic care is consistently defined, its operationalization varies significantly. The study highlights key elements that can enhance the effectiveness of dyadic care despite existing challenges related to funding, coordination, and resource limitations.

Medicaid Prior Authorization and Discontinuation of Buprenorphine

Jun 24, 2026

The authors investigate how Medicaid's utilization management policies, specifically prior authorization (PA), affect the duration of buprenorphine treatment episodes for opioid use disorder. Their analysis of national prescription claims data reveals that buprenorphine discontinuation rates are high across all Medicaid plans, with a notable decline in treatment continuation observed within the first three months, particularly among managed care organization (MCO) plans with PA. The findings suggest a need for further research into additional insurer policies that may impact treatment adherence.

Trends in Public Opinion About US Illicit Drug Policy: Results From the 2000 to 2025 Gallup Survey

Jun 24, 2026

This study investigates American perceptions of progress in illicit drug policy and the severity of the drug problem from 2000 to 2025, utilizing data from the Gallup Poll Social Survey. The findings reveal that less than half of Americans consistently perceive progress against illicit drugs, with significant partisan differences influencing these perceptions, particularly in the context of political leadership. The authors highlight that increasing political polarization may hinder the development of a unified national drug control strategy.

Prevalence of Alcohol Use Disorder and Alcohol-related Liver Disease in Women Undergoing Cervical Cancer Screening: A Missed Opportunity to Screen?

Jun 18, 2026

This study investigates the prevalence of alcohol use disorder (AUD) and alcohol-related liver disease (ALD) among women undergoing cervical cancer screening, aiming to determine if these visits serve as missed opportunities for identifying AUD. The findings reveal that approximately 1 in 50 women screened had AUD, with a significant portion of those hospitalized having previously attended cervical cancer screenings where AUD was undiagnosed. The authors suggest that implementing standardized screening for AUD during these visits could help mitigate the risks associated with harmful alcohol use.

ASAM Consensus Standards for Substance Use Disorder Care Capabilities in Hospitals and Emergency Departments

Jun 18, 2026

The authors aim to establish consensus standards for substance use disorder (SUD) care capabilities in hospitals and emergency departments, addressing the significant morbidity and costs associated with untreated SUD. Through a comprehensive development process, they identified seven core competencies essential for effective SUD care, which serve as a framework for hospitals to improve their treatment protocols. The goal is to unify expectations and enhance the quality of care for patients with SUD in medical settings.

Use of Medication for Addiction Treatment Among Physicians and Pharmacists Monitored for Substance Use Disorder by One State Physician Health Program

Jun 12, 2026

This study investigates the use of medication for addiction treatment (MAT) among physicians and pharmacists monitored for substance use disorder by a state physician health program over 30 years. The authors aimed to assess patterns of MAT utilization and its impact on monitoring outcomes, finding that over 70% of participants achieved positive outcomes regardless of MAT use, suggesting that all FDA-approved MAT should be considered for this population when clinically appropriate.

An Equitable Behavioral Engagement Framework for Stimulant Medication Treatment in Methamphetamine Use Disorder

Jun 12, 2026

The authors aim to address the challenges of implementing long-acting methylphenidate as a treatment for methamphetamine use disorder, particularly in light of its regulatory status and the need for equitable access. They propose a behavioral engagement framework that includes five domains—adherence, abstinence progress, attendance, alternative activities, and accessing support—to guide the initiation and monitoring of stimulant medication in clinical practice. This structured approach seeks to enhance safety and accountability while ensuring a fair application of this emerging treatment option.

Case Report: Oral-Nasal Damage in a Person Using Fentanyl and Xylazine

Jun 8, 2026

The authors aim to document the oral-nasal damage resulting from the intranasal use of fentanyl and xylazine, substances that have become increasingly common in illicit drug use. They present a case of a 39-year-old woman who experienced severe nasal and palate damage, highlighting the need for clinicians to recognize and address the potential complications associated with these drugs. This case underscores the importance of appropriate referrals for treatment of substance use disorders and related physical damage.

Perspectives of Youth Experiencing Homelessness on Substance Use and Harm Reduction: A Qualitative Youth Participatory Action Research Study

Jun 8, 2026

This study seeks to understand the perspectives of youth experiencing homelessness (YEH) regarding substance use and harm reduction, as well as to identify ways to improve support from healthcare providers and youth-serving agencies. Through focus groups with YEH, the authors highlight key themes such as the need for compassionate care, the importance of individualized approaches, and the necessity of waiving sobriety requirements in service settings. The findings emphasize the value of incorporating the voices of YEH in shaping effective health interventions and support systems.

Postmortem Toxicology Positivity for Medications for Opioid Use Disorder in Illinois Unintentional Opioid Overdose Deaths 2019-2024

Jun 4, 2026

This study aims to investigate the prevalence of medications for opioid use disorder (MOUD) in unintentional opioid overdose deaths attributed to fentanyl in Illinois from 2019 to 2024. The findings reveal that MOUD detection was consistently low, with only methadone showing a significant protective association against fentanyl-related overdose deaths, while buprenorphine and naltrexone did not demonstrate a significant effect.